1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D67753DF106D61B365257917001F7B2D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/D67753DF106D61B365257917001F7B2D!OpenDocument
18
19OpenDocument
2054.198.139.112
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Complimentary Excerpt: Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls

DB Image

Excerpt in Cart

ID: MD-269


Features:

Metrics, Graphics


Pages/Slides: 4


Published: Pre-2016


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".


To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5159 "Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal, and Regulatory Pitfalls."


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.